Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes

Heart

Volumn 92, Issue 9, 2006, Pages 1278-1284

  Vijayalakshmi, K ^a   Whittaker, V J ^b   Kunadian, B ^a   Graham, J ^a   Wright, R A ^a   Hall, J A ^a   Sutton, A ^a   De Belder, Mark A ^a  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b TEESSIDE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; SODIUM CHLORIDE; VERAPAMIL;

ABSENCE OF SIDE EFFECTS; ACUTE CORONARY SYNDROME; ADULT; ANGIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOSE RESPONSE; ECHOCARDIOGRAPHY; FEMALE; HEART BLOCK; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADENOSINE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; ECHOCARDIOGRAPHY; FEASIBILITY STUDIES; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SYNDROME; TREATMENT OUTCOME; VASODILATOR AGENTS; VERAPAMIL;

EID: 33748070798     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.075077     Document Type: Article

References (22)

1. Piani R, Palik G, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994;89:2514-8.
2. Bates E, Krell M, Dean E, et al. Demonstration of no-reflow phenomenon by digital coronary arteriography. Am J Cardiol 1986;57:177-8.
3. Feld H, Lichstein E, Schachter J, et al. Early and late angiographic findings of the no-reflow phenomenon following direct angioplasty as primary treatment for acute myocardial infarction. Am Heart J 1992;123:782-4.
4. Kloner R, Ganote C. The no-reflow phenomenon after temporary occlusion in the dog. J Clin Invest 1974;54:1508.
5. Werner G, Lang K, Kuehnert H, et al. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 2002;57:444-51.
6. Oldenburg O, Eggerbrecht H, Herrmann J, et al. Dose-dependent effects of intracoronary verapamil on systemic and coronary hemodynamics. Cardiovasc Drugs Ther 2000;14:651-5.
7. Kaplan B, Benzuly K, Kinn J, et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Catheter Cardiovasc Interv 1996;39:113-8.
8. Michaels A, Appleby M, Otten M, et al. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results or the randomised, controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invasive Cardiol 2002;14:299-302.
9. Lim S, Bae E, Jeong M, et al. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. Circ J 2004;68:928-32.
10. Taniyama Y, Ito H, Iwakura K. Beneficial effects of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997;30:1193-9.
11. Wilson R, Wyche K, Christensen B, et al. Effects of adenosine on human coronary arterial circulation. Circulation 1990;82:1595-606.
12. Marzilli M, Orsini E, Marracini P, et al. Beneficial effects of intracoronary adenosine as adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000;101:2154-9.
13. Vijayalakshmi K, Ashton V, Wright R, et al. Corrected TIMI frame count (cTFC): applicability in modern digital catheter laboratories when different frame acquisition rates are used. Catheter Cardiovasc Interv 2004;63:426-32.
14. Gibson MC, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879-88.
15. The TIMI Study Group. Thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med 1985;312:932-6.
16. Van't Hof A, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation 1998;97:2302-6.
17. Gibson C, Murphy S, Rizzo M. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Circulation 1999;99:1945-50.
18. Olafsson B, Forman M, Puett D, et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine. Circulation 1987;76:1135-45.
19. Van der Heide R, Reimer K. Effects of adenosine therapy at reperfusion on myocardial infarct size in dogs. Cardiovasc Res 1996;31:711-8.
20. Henriques J, Zijlstra F, van't Hof A, et al. Angiographic assessment of reperfusion in acute myocardial infarction. Circulation 2003;107:2115-9.
21. Stoel M, Zijlstra F, Visser C. Frame count reserve. Circulation 2003;107:3034-9.
22. Manginas AM, Gatzov PM, Chasikidis CM, et al. Estimation of coronary flow reserve using the thrombolysis in myocardial infarction (TIMI) frame count method. Am J Cardiol 1999;83:1562-5.